BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation

NCT05622123 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether a faecal microbiota transplant can help assess the relationship between the remaining beta cells in the pancreas and their function in people with type 1 diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design open-label (no blinding) study

Participants 20 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2023-02 · est. completion 2024-03

Where 1 site · Netherlands

What this study is testing ClinicalTrials.gov NCT05622123 ↗

Description as written by the study sponsor.

The main goal is to investigate whether beta cell mass is correlated to beta cell function after autologous faecal microbial transplantation (FMT) in patients with newly diagnosed type 1 diabetes

Treatments tested

68Ga-NODAGA-Exendin-4 Drug

PET/CT imaging after injection with 68Ga-NODAGA-exendin-4

Main thing measured	Correlation between residual beta cell mass and function
Sponsor	Radboud University Medical Center
Conditions studied	Type 1 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05622123 ↗